Invitae Corp (NYSE:NVTA)
0.019 USD
-0.011 35.593%Sponsored Reports
Previous Close (in USD) | 0.0295 |
---|---|
Change | -0.011 35.593% |
52 W H/L (in USD) | 2.940/0.360 |
EBITDA (in USD) | -353.937M |
PE Ratio | -- |
Volume | 22459258 |
Diluted Eps TTM | -5.36 |
Total Assets (in USD) | 1954.116M |
---|---|
Total Liabilities (in USD) | 1852.28M |
Revenue TTM (in USD) | 481.583M |
Cash (in USD) | 257.489M |
Market Cap (in USD) | 206.476 M |
Revenue Per Share TTM | 1.864 |
Gross Profit TTM (in USD) | 99.047M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Invitae Corp
Employees: 1700
Key Executives
Sr. No. | Name | Title | Year Born |
---|---|---|---|
1. | Mr. Kenneth D. Knight | Pres, CEO & Director | 1961 |
2. | Ms. Yafei Wen | Chief Financial Officer | 1973 |
3. | Mr. Thomas R. Brida | Gen. Counsel, Chief Compliance Officer & Sec. | 1971 |
4. | Dr. Robert L. Nussbaum M.D. | Chief Medical Officer | 1950 |
5. | Ms. Shelly D. Guyer | Chief Sustainability Officer | 1960 |
6. | Mr. Robert F. Werner | Chief Accounting Officer & Principal Accounting Officer | 1973 |
7. | Ms. Hoki Luk | Head of Investor Relations and Capital Markets | 1976 |
8. | Mr. Lee Bendekgey J.D. | Chief Policy Officer | 1958 |
9. | Glenn Medalle | Head of Talent | NA |
10. | Ms. Desarie French | Chief Talent Officer | NA |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
TMO
Thermo Fisher Scientific Inc |
+3.390 0.554% | 616.11 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
DHR
Danaher Corporation |
+2.290 0.858% | 268.3 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
IDXX
IDEXX Laboratories Inc |
-5.950 1.221% | 489.37 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
IQV
IQVIA Holdings Inc |
+0.760 0.303% | 251.01 | 37.820 | 19.685 | 2.764 | 7.195 | 3.607 | 17.031 |
Income Statement
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Income Before Tax | -3151.197M | -415.863M | -714.27M | -260.415M | -132.155M |
Minority Interest | - | - | - | - | - |
Net Income | -3106.293M | -379.006M | -608.87M | -241.965M | -129.355M |
Selling General Administrative | 192.314M | 248.07M | 324.573M | 79.07M | 52.227M |
Gross Profit | 99.047M | 111.78M | 81.323M | 98.721M | 67.594M |
Reconciled Depreciation | 142.071M | 80.472M | 39.05M | 16.206M | 13.54M |
Ebit | -714.236M | -778.287M | -652.172M | -244.112M | -125.125M |
Ebitda | -564.111M | -672.137M | -645.454M | -231.797M | -111.585M |
Depreciation And Amortization | 150.125M | 106.15M | 6.718M | 12.315M | 13.54M |
Operating Income | -714.236M | -778.287M | -652.172M | -244.112M | -122.557M |
Other Operating Expenses | 1230.539M | 1238.736M | 931.77M | 460.936M | 270.256M |
Interest Expense | 56.747M | 49.9M | 29.766M | 12.412M | 7.03M |
Tax Provision | -44.904M | -36.857M | -105.4M | -18.45M | -2.8M |
Interest Income | - | - | - | 12.412M | 7.03M |
Net Interest Income | -56.747M | -49.9M | -29.766M | -12.412M | -7.03M |
Income Tax Expense | -44.904M | -36.857M | -105.4M | -18.45M | -2.8M |
Total Revenue | 516.303M | 460.449M | 279.598M | 216.824M | 147.699M |
Total Operating Expenses | 813.283M | 890.067M | 733.495M | 342.833M | 190.151M |
Cost Of Revenue | 417.256M | 348.669M | 198.275M | 118.103M | 80.105M |
Total Other Income Expense Net | -2436.961M | 362.424M | -62.098M | -16.303M | -2.568M |
Net Income From Continuing Ops | -3106.293M | -379.006M | -602.17M | -241.965M | -129.355M |
Net Income Applicable To Common Shares | -3106.293M | -379.006M | -602.17M | -241.965M | -129.355M |
Balance Sheet
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Total Assets | 1954.116M | 4919.567M | 3423.785M | 781.601M | 282.959M |
Intangible Assets | 1012.549M | 1187.994M | 981.845M | 125.175M | 30.469M |
Other Current Assets | 19.496M | 33.691M | 20.2M | 18.032M | 13.258M |
Total Liab | 1852.28M | 1941.169M | 1454.192M | 401.961M | 121.12M |
Total Stockholder Equity | 101.836M | 2978.398M | 1969.593M | 379.64M | 161.839M |
Other Current Liab | 69.574M | 97.022M | 79.68M | 63.385M | 25.802M |
Common Stock | 0.025M | 0.023M | 0.019M | 0.01M | 0.008M |
Capital Stock | 0.025M | 0.023M | 0.019M | 0.01M | 0.008M |
Retained Earnings | -4829.141M | -1722.848M | -1367.547M | -758.677M | -516.712M |
Good Will | 0M | 2283.059M | 1856.923M | 126.777M | 50.095M |
Other Assets | -3.858M | 33.826M | 19.874M | 7.264M | 9.07M |
Cash | 257.489M | 923.25M | 124.794M | 151.389M | 112.158M |
Cash And Equivalents | - | - | - | - | - |
Total Current Liabilities | 108.093M | 144.095M | 121.745M | 81.86M | 36.312M |
Current Deferred Revenue | 4.814M | 9.431M | 6.378M | 1.429M | 0.761M |
Net Debt | 1493.514M | 800.846M | 325.343M | 167.437M | -34.369M |
Short Term Debt | 19.721M | 16.515M | 10.484M | 6.725M | 1.937M |
Short Long Term Debt | - | - | - | - | - |
Short Long Term Debt Total | 1751.003M | 1724.096M | 450.137M | 318.826M | 77.789M |
Other Stockholder Equity | 4931.032M | 4701.23M | 3337.12M | 1138.316M | 678.548M |
Property Plant Equipment | 215.286M | 235.883M | 66.102M | 37.747M | 27.886M |
Total Current Assets | 693.13M | 1178.805M | 453.932M | 442.398M | 165.439M |
Long Term Investments | - | - | - | - | 0M |
Short Term Investments | 289.611M | 122.121M | 229.186M | 240.436M | 13.727M |
Net Receivables | 96.148M | 66.227M | 47.722M | 32.541M | 26.296M |
Long Term Debt | 1593.116M | 1577.529M | 388.173M | 268.755M | 74.477M |
Inventory | 30.386M | 33.516M | 32.03M | 6.6M | 8.3M |
Accounts Payable | 13.984M | 21.127M | 25.203M | 10.321M | 7.812M |
Accumulated Other Comprehensive Income | -0.08M | -0.007M | 0.001M | -0.009M | -0.005M |
Non Currrent Assets Other | 33.151M | 33.826M | 19.874M | 12.864M | 9.07M |
Non Current Assets Total | 1260.986M | 3740.762M | 2969.853M | 339.203M | 117.52M |
Capital Lease Obligations | 157.887M | 146.567M | 61.964M | 50.071M | 1.375M |
Long Term Debt Total | - | 1577.529M | 388.173M | 268.755M | 75.852M |
Cash Flow
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Investments | -174.803M | 99.336M | 10.061M | -226.417M | 42.743M |
Total Cashflows From Investing Activities | -174.803M | -204.08M | -400.583M | -280.31M | 35.773M |
Total Cash From Financing Activities | 1.758M | 1565.94M | 673.844M | 464.771M | 157.152M |
Net Income | -3106.293M | -379.006M | -608.87M | -241.965M | -129.355M |
Change In Cash | -666.006M | 802.045M | -26.092M | 39.408M | 100.705M |
Begin Period Cash Flow | 933.525M | 131.48M | 157.572M | 118.164M | 17.459M |
End Period Cash Flow | 267.519M | 933.525M | 131.48M | 157.572M | 118.164M |
Total Cash From Operating Activities | -492.961M | -559.815M | -299.354M | -145.053M | -92.22M |
Depreciation | 142.071M | 80.472M | 39.05M | 16.206M | 13.54M |
Other Cashflows From Investing Activities | - | -1.3M | -387.779M | -33.846M | -1M |
Dividends Paid | - | - | - | - | - |
Change To Inventory | 3.13M | -1.486M | -7.832M | 11.318M | 2.119M |
Sale Purchase Of Stock | - | 23.767M | 284.203M | 9.47M | 17.511M |
Other Cashflows From Financing Activities | -10.647M | 1111.669M | 130.953M | 328.352M | 89.3M |
Capital Expenditures | 53.309M | 54.72M | 22.865M | 20.047M | 5.97M |
Change In Working Capital | -25.341M | -27.617M | 15.972M | 8.771M | -3.752M |
Other Non Cash Items | 2342.202M | -376.882M | 201.147M | 14.437M | 9.359M |
Free Cash Flow | -546.27M | -614.535M | -322.219M | -165.1M | -98.19M |
Funds
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | ARK Innovation ETF | 9 months ago | 19344290 |
2. | ARK Disruptive Innovation Full Composite | 11 months ago | 18882867 |
3. | Nikko AM ARK Disruptive Innovation A USD | 10 months ago | 11253972 |
4. | ARK Genomic Revolution ETF | 9 months ago | 9152119 |
5. | ARK Genomic Revolution | 11 months ago | 9058622 |
6. | Vanguard Total Stock Mkt Idx Inv | 9 months ago | 8208345 |
7. | iShares Russell 2000 ETF | 9 months ago | 6326347 |
8. | Nikko AM ARK Pstv Chg Innovt P JPY Acc | 10 months ago | 4341307 |
9. | Vanguard Institutional Extnd Mkt Idx Tr | 9 months ago | 3688951 |
10. | Fidelity® Small Cap Index | 11 months ago | 2422829 |
11. | State St Russell Sm/Mid Cp® Indx NL Cl C | 9 months ago | 2348236 |
12. | iShares Russell 2000 Growth ETF | 9 months ago | 2051633 |
13. | SPDR® S&P Kensho New Economies Comps ETF | 9 months ago | 1796092 |
14. | iShares Biotechnology ETF | 9 months ago | 1781310 |
15. | JPM Thematics Genetic Thrps C2 Acc USD | 10 months ago | 1496659 |
16. | Invesco FTSE RAFI US 1500 Small-Mid ETF | 9 months ago | 1431776 |
17. | American Beacon ARK Transfmt Innov R5 | 10 months ago | 1300112 |
18. | Schwab US Small-Cap ETF™ | 9 months ago | 1269438 |
19. | State St Russell Sm Cap® Indx SL Cl I | 9 months ago | 999939 |
20. | iShares Genomics Immnlgy & Hlthcr ETF | 9 months ago | 922930 |
Institutions
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | ARK Investment Management LLC | 11 months ago | 32942606 |
2. | BlackRock Inc | 11 months ago | 20797979 |
3. | Nikko Asset Management Americas Inc | 11 months ago | 16764480 |
4. | Sumitomo Mitsui Trust Holdings Inc | 11 months ago | 16764480 |
5. | Vanguard Group Inc | 11 months ago | 13527507 |
6. | State Street Corporation | 11 months ago | 7958947 |
7. | Geode Capital Management, LLC | 11 months ago | 5124199 |
8. | Redmile Group, LLC | 11 months ago | 2280403 |
9. | Northern Trust Corp | 11 months ago | 2241489 |
10. | Charles Schwab Investment Management Inc | 11 months ago | 2103253 |
11. | State Treasurer State Of Michigan | 11 months ago | 1959939 |
12. | Baker Bros Advisors LP | 11 months ago | 1764546 |
13. | JPMorgan Chase & Co | 11 months ago | 1672955 |
14. | Mirae Asset Global Investments (Korea) Co Ltd | 11 months ago | 1652650 |
15. | Morgan Stanley - Brokerage Accounts | 11 months ago | 1635925 |
16. | Goldman Sachs Group Inc | 11 months ago | 1619138 |
17. | Susquehanna International Group, LLP | 11 months ago | 1582856 |
18. | Amvescap Plc. | 11 months ago | 1505866 |
19. | Barclays PLC | 11 months ago | 905531 |
20. | Bank of New York Mellon Corp | 11 months ago | 877217 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).